A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia
A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5 of therapy if signs and symptoms had improved. The...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of infectious diseases 1998, Vol.30 (4), p.397-404 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 404 |
|---|---|
| container_issue | 4 |
| container_start_page | 397 |
| container_title | Scandinavian journal of infectious diseases |
| container_volume | 30 |
| creator | NORRBY, S. R PETERMANN, W WILLCOX, P. A VETTER, N SALEWSKI, E |
| description | A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5 of therapy if signs and symptoms had improved. The minimum treatment duration was 5 d, except for treatment failure, and the median 8 d. The primary efficacy analysis was based on the per-protocol assessment of the clinical cure rate determined 2-5 d after the end of treatment in the per-protocol (PP) population (levofloxacin 127, ceftriaxone 139). Of 625 patients enrolled and randomized, 6 received no treatment, giving an intention-to-treat (ITT) population of 619 (levofloxacin 314, ceftriaxone 305). At the clinical endpoint, 2-5 d after the end of treatment, the cure rates for levofloxacin and ceftriaxone were similar in both the ITT (76% and 75%, respectively) and PP (87% and 86%, respectively) populations. Both drugs were well tolerated. Twice-daily levofloxacin 500 mg, either i.v. or as sequential iv/oral therapy, was as effective as i.v. once-daily ceftriaxone 4 g in the treatment of hospitalized patients with pneumonia and offers the advantage of sequential therapy. |
| doi_str_mv | 10.1080/00365549850160710 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_2430106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1080_00365549850160710</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-4dfdcda5bf84db4529cce70187f5cf400a1ba258713616a779c22017177201963</originalsourceid><addsrcrecordid>eNp9kE1rFEEQhhtR4hr9AR6EPnidWDUzPT2DXsKiibBgwHgeavuD7TDTvXT3Jll_vb3sGhAhp4J636c-XsbeI1wg9PAJoOmEaIdeAHYgEV6wBXYCKxx6eMkWB70qhv41e5PSHQC0XQNn7GzoUYq6XrDpki_DvKVI2d0b_jPv9J4Hy1fmPtgpPJJynpPXfGlsjo4egze8tPLG8NtoKM_G5wNwHdLWZZrcb6P5TZlW-ok_uLzhN97s5uAdvWWvLE3JvDvVc_br29fb5XW1-nH1fXm5qlTbQK5abbXSJNa2b_W6FfWglJGAvbRC2RaAcE216CU2HXYk5aDqGlCilKUMXXPO8DhXxZBSNHbcRjdT3I8I4yG48b_gCvPhyGx369noJ-KUVNE_nnRKiiYbySuXnmx1uRzhsPrL0ea8DXGmhxAnPWbaTyH-ZZrnrvj8D74xNOWNomjGu7CLvqT2zA9_ABMBmtU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia</title><source>MEDLINE</source><source>Taylor & Francis:Master (3349 titles)</source><source>Taylor & Francis Medical Library - CRKN</source><creator>NORRBY, S. R ; PETERMANN, W ; WILLCOX, P. A ; VETTER, N ; SALEWSKI, E</creator><creatorcontrib>NORRBY, S. R ; PETERMANN, W ; WILLCOX, P. A ; VETTER, N ; SALEWSKI, E</creatorcontrib><description>A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5 of therapy if signs and symptoms had improved. The minimum treatment duration was 5 d, except for treatment failure, and the median 8 d. The primary efficacy analysis was based on the per-protocol assessment of the clinical cure rate determined 2-5 d after the end of treatment in the per-protocol (PP) population (levofloxacin 127, ceftriaxone 139). Of 625 patients enrolled and randomized, 6 received no treatment, giving an intention-to-treat (ITT) population of 619 (levofloxacin 314, ceftriaxone 305). At the clinical endpoint, 2-5 d after the end of treatment, the cure rates for levofloxacin and ceftriaxone were similar in both the ITT (76% and 75%, respectively) and PP (87% and 86%, respectively) populations. Both drugs were well tolerated. Twice-daily levofloxacin 500 mg, either i.v. or as sequential iv/oral therapy, was as effective as i.v. once-daily ceftriaxone 4 g in the treatment of hospitalized patients with pneumonia and offers the advantage of sequential therapy.</description><identifier>ISSN: 0036-5548</identifier><identifier>EISSN: 1651-1980</identifier><identifier>DOI: 10.1080/00365549850160710</identifier><identifier>PMID: 9817522</identifier><identifier>CODEN: SJIDB7</identifier><language>eng</language><publisher>Basingstoke: Informa UK Ltd</publisher><subject><![CDATA[Adolescent ; Adult ; Aged ; Aged, 80 and over ; Anti-Infective Agents - administration & dosage ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Bacterial diseases of the respiratory system ; Biological and medical sciences ; Ceftriaxone - administration & dosage ; Ceftriaxone - adverse effects ; Ceftriaxone - therapeutic use ; Cephalosporins - administration & dosage ; Cephalosporins - adverse effects ; Cephalosporins - therapeutic use ; Community-Acquired Infections - drug therapy ; Female ; Gram-Negative Bacteria - isolation & purification ; Gram-Positive Bacteria - isolation & purification ; Hospitalization ; Human bacterial diseases ; Humans ; Infectious diseases ; International Cooperation ; Levofloxacin ; Male ; Medical sciences ; Middle Aged ; Ofloxacin - administration & dosage ; Ofloxacin - adverse effects ; Ofloxacin - therapeutic use ; Pharmacology. Drug treatments ; Pneumonia, Bacterial - drug therapy ; Pneumonia, Bacterial - microbiology ; Treatment Outcome]]></subject><ispartof>Scandinavian journal of infectious diseases, 1998, Vol.30 (4), p.397-404</ispartof><rights>1998 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1998</rights><rights>1998 INIST-CNRS</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-4dfdcda5bf84db4529cce70187f5cf400a1ba258713616a779c22017177201963</citedby><cites>FETCH-LOGICAL-c430t-4dfdcda5bf84db4529cce70187f5cf400a1ba258713616a779c22017177201963</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/00365549850160710$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/00365549850160710$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,780,784,4024,27923,27924,27925,59647,59753,60436,60542,61221,61256,61402,61437</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2430106$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9817522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>NORRBY, S. R</creatorcontrib><creatorcontrib>PETERMANN, W</creatorcontrib><creatorcontrib>WILLCOX, P. A</creatorcontrib><creatorcontrib>VETTER, N</creatorcontrib><creatorcontrib>SALEWSKI, E</creatorcontrib><title>A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia</title><title>Scandinavian journal of infectious diseases</title><addtitle>Scand J Infect Dis</addtitle><description>A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5 of therapy if signs and symptoms had improved. The minimum treatment duration was 5 d, except for treatment failure, and the median 8 d. The primary efficacy analysis was based on the per-protocol assessment of the clinical cure rate determined 2-5 d after the end of treatment in the per-protocol (PP) population (levofloxacin 127, ceftriaxone 139). Of 625 patients enrolled and randomized, 6 received no treatment, giving an intention-to-treat (ITT) population of 619 (levofloxacin 314, ceftriaxone 305). At the clinical endpoint, 2-5 d after the end of treatment, the cure rates for levofloxacin and ceftriaxone were similar in both the ITT (76% and 75%, respectively) and PP (87% and 86%, respectively) populations. Both drugs were well tolerated. Twice-daily levofloxacin 500 mg, either i.v. or as sequential iv/oral therapy, was as effective as i.v. once-daily ceftriaxone 4 g in the treatment of hospitalized patients with pneumonia and offers the advantage of sequential therapy.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Infective Agents - administration & dosage</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Bacterial diseases of the respiratory system</subject><subject>Biological and medical sciences</subject><subject>Ceftriaxone - administration & dosage</subject><subject>Ceftriaxone - adverse effects</subject><subject>Ceftriaxone - therapeutic use</subject><subject>Cephalosporins - administration & dosage</subject><subject>Cephalosporins - adverse effects</subject><subject>Cephalosporins - therapeutic use</subject><subject>Community-Acquired Infections - drug therapy</subject><subject>Female</subject><subject>Gram-Negative Bacteria - isolation & purification</subject><subject>Gram-Positive Bacteria - isolation & purification</subject><subject>Hospitalization</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>International Cooperation</subject><subject>Levofloxacin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ofloxacin - administration & dosage</subject><subject>Ofloxacin - adverse effects</subject><subject>Ofloxacin - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Pneumonia, Bacterial - microbiology</subject><subject>Treatment Outcome</subject><issn>0036-5548</issn><issn>1651-1980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1rFEEQhhtR4hr9AR6EPnidWDUzPT2DXsKiibBgwHgeavuD7TDTvXT3Jll_vb3sGhAhp4J636c-XsbeI1wg9PAJoOmEaIdeAHYgEV6wBXYCKxx6eMkWB70qhv41e5PSHQC0XQNn7GzoUYq6XrDpki_DvKVI2d0b_jPv9J4Hy1fmPtgpPJJynpPXfGlsjo4egze8tPLG8NtoKM_G5wNwHdLWZZrcb6P5TZlW-ok_uLzhN97s5uAdvWWvLE3JvDvVc_br29fb5XW1-nH1fXm5qlTbQK5abbXSJNa2b_W6FfWglJGAvbRC2RaAcE216CU2HXYk5aDqGlCilKUMXXPO8DhXxZBSNHbcRjdT3I8I4yG48b_gCvPhyGx369noJ-KUVNE_nnRKiiYbySuXnmx1uRzhsPrL0ea8DXGmhxAnPWbaTyH-ZZrnrvj8D74xNOWNomjGu7CLvqT2zA9_ABMBmtU</recordid><startdate>1998</startdate><enddate>1998</enddate><creator>NORRBY, S. R</creator><creator>PETERMANN, W</creator><creator>WILLCOX, P. A</creator><creator>VETTER, N</creator><creator>SALEWSKI, E</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1998</creationdate><title>A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia</title><author>NORRBY, S. R ; PETERMANN, W ; WILLCOX, P. A ; VETTER, N ; SALEWSKI, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-4dfdcda5bf84db4529cce70187f5cf400a1ba258713616a779c22017177201963</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Infective Agents - administration & dosage</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Bacterial diseases of the respiratory system</topic><topic>Biological and medical sciences</topic><topic>Ceftriaxone - administration & dosage</topic><topic>Ceftriaxone - adverse effects</topic><topic>Ceftriaxone - therapeutic use</topic><topic>Cephalosporins - administration & dosage</topic><topic>Cephalosporins - adverse effects</topic><topic>Cephalosporins - therapeutic use</topic><topic>Community-Acquired Infections - drug therapy</topic><topic>Female</topic><topic>Gram-Negative Bacteria - isolation & purification</topic><topic>Gram-Positive Bacteria - isolation & purification</topic><topic>Hospitalization</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>International Cooperation</topic><topic>Levofloxacin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ofloxacin - administration & dosage</topic><topic>Ofloxacin - adverse effects</topic><topic>Ofloxacin - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Pneumonia, Bacterial - microbiology</topic><topic>Treatment Outcome</topic><toplevel>online_resources</toplevel><creatorcontrib>NORRBY, S. R</creatorcontrib><creatorcontrib>PETERMANN, W</creatorcontrib><creatorcontrib>WILLCOX, P. A</creatorcontrib><creatorcontrib>VETTER, N</creatorcontrib><creatorcontrib>SALEWSKI, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Scandinavian journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>NORRBY, S. R</au><au>PETERMANN, W</au><au>WILLCOX, P. A</au><au>VETTER, N</au><au>SALEWSKI, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia</atitle><jtitle>Scandinavian journal of infectious diseases</jtitle><addtitle>Scand J Infect Dis</addtitle><date>1998</date><risdate>1998</risdate><volume>30</volume><issue>4</issue><spage>397</spage><epage>404</epage><pages>397-404</pages><issn>0036-5548</issn><eissn>1651-1980</eissn><coden>SJIDB7</coden><abstract>A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5 of therapy if signs and symptoms had improved. The minimum treatment duration was 5 d, except for treatment failure, and the median 8 d. The primary efficacy analysis was based on the per-protocol assessment of the clinical cure rate determined 2-5 d after the end of treatment in the per-protocol (PP) population (levofloxacin 127, ceftriaxone 139). Of 625 patients enrolled and randomized, 6 received no treatment, giving an intention-to-treat (ITT) population of 619 (levofloxacin 314, ceftriaxone 305). At the clinical endpoint, 2-5 d after the end of treatment, the cure rates for levofloxacin and ceftriaxone were similar in both the ITT (76% and 75%, respectively) and PP (87% and 86%, respectively) populations. Both drugs were well tolerated. Twice-daily levofloxacin 500 mg, either i.v. or as sequential iv/oral therapy, was as effective as i.v. once-daily ceftriaxone 4 g in the treatment of hospitalized patients with pneumonia and offers the advantage of sequential therapy.</abstract><cop>Basingstoke</cop><pub>Informa UK Ltd</pub><pmid>9817522</pmid><doi>10.1080/00365549850160710</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0036-5548 |
| ispartof | Scandinavian journal of infectious diseases, 1998, Vol.30 (4), p.397-404 |
| issn | 0036-5548 1651-1980 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_2430106 |
| source | MEDLINE; Taylor & Francis:Master (3349 titles); Taylor & Francis Medical Library - CRKN |
| subjects | Adolescent Adult Aged Aged, 80 and over Anti-Infective Agents - administration & dosage Anti-Infective Agents - adverse effects Anti-Infective Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Bacterial diseases of the respiratory system Biological and medical sciences Ceftriaxone - administration & dosage Ceftriaxone - adverse effects Ceftriaxone - therapeutic use Cephalosporins - administration & dosage Cephalosporins - adverse effects Cephalosporins - therapeutic use Community-Acquired Infections - drug therapy Female Gram-Negative Bacteria - isolation & purification Gram-Positive Bacteria - isolation & purification Hospitalization Human bacterial diseases Humans Infectious diseases International Cooperation Levofloxacin Male Medical sciences Middle Aged Ofloxacin - administration & dosage Ofloxacin - adverse effects Ofloxacin - therapeutic use Pharmacology. Drug treatments Pneumonia, Bacterial - drug therapy Pneumonia, Bacterial - microbiology Treatment Outcome |
| title | A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T09%3A05%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Comparative%20Study%20of%20Levofloxacin%20and%20Ceftriaxone%20in%20the%20Treatment%20of%20Hospitalized%20Patients%20with%20Pneumonia&rft.jtitle=Scandinavian%20journal%20of%20infectious%20diseases&rft.au=NORRBY,%20S.%20R&rft.date=1998&rft.volume=30&rft.issue=4&rft.spage=397&rft.epage=404&rft.pages=397-404&rft.issn=0036-5548&rft.eissn=1651-1980&rft.coden=SJIDB7&rft_id=info:doi/10.1080/00365549850160710&rft_dat=%3Cinformahealthcare_pasca%3E10_1080_00365549850160710%3C/informahealthcare_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9817522&rfr_iscdi=true |